Sage Therapeutics, Inc. (SAGE)

Market Cap	343.18M
Revenue (ttm)	106.40M
Net Income (ttm)	-337.59M
Shares Out	61.17M
EPS (ttm)	-5.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,148,019
Open	4.99
Previous Close	5.00
Day's Range	4.95 - 5.62
52-Week Range	4.62 - 28.26
Beta	0.93
Analysts	Hold
Price Target	11.53 (+105.53%)
Earnings Date	Feb 12, 2025

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2014
• Employees: 487
• Stock Exchange: NASDAQ
• Ticker Symbol: SAGE
• Website: https://www.sagerx.com

Financial Performance

In 2023, Sage Therapeutics's revenue was $86.46 million, an increase of 1024.84% compared to the previous year's $7.69 million. Losses were -$541.49 million, 1.63% more than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for SAGE stock is "Hold." The 12-month stock price forecast is $11.53, which is an increase of 105.53% from the latest price.

Price Target

$11.53

(105.53% upside)

Analyst Consensus: Hold